TrialBMC medicine2023

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).

Meng Chai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.